Clinical Trial Update: OSCAR I STUDY - The ONCObind CTC Removal Study [NA]

View source ↗

Summary

The OSCAR I study evaluating the ONCObind CTC removal system for pancreatic ductal adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• ONCObind CTC Removal System

Snippet

Sponsor: ExThera Medical Corporation | Conditions: Pancreatic Ductal Adenocarcinoma (PDAC) | NA | Status: COMPLETED